Armata Pharmaceuticals, Inc. — Form 8-K
Filed July 20, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 71/100
What the filing says
Armata Pharmaceuticals submitted its complete Phase 3 superiority protocol and comprehensive FDA responses for AP-SA02 (S. aureus bacteriophage therapeutic), with Phase 3 initiation planned for H2 2026. The company received an additional $2.5 million from the Department of Defense (total DoD funding now $28.7 million), and promoted David House to Chief Financial Officer from Senior Vice President of Finance.
Why this rating
Phase 3 protocol submission is major clinical milestone for $21.1M company; $2.5M DoD award is ~12% of market cap. Executive stability supports late-stage execution.
See more from July 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.